Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. - sprookjes - yvandenbroek - TriplyDB

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.

http://www.wikidata.org/entity/Q37402790

about

Iron reduction response and demographic differences between diabetics and non-diabetics with cardiovascular disease entered into a controlled clinical trial.Dioxygen and Metabolism; Dangerous Liaisons in Cardiac Function and Disease.

P2860

Q47230788-29E2092B-8EEB-41EA-89DB-B2E8CACCE685 Q49247394-27920A5E-3F69-45C4-99D9-0BC758F3B0F6

P2860

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.

http://www.wikidata.org/entity/Q37402790

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Does Glucagon-like Peptide-1 A ...... rimental and Clinical Studies.

@en

Does Glucagon-like Peptide-1 A ...... rimental and Clinical Studies.

@nl

type

label

Does Glucagon-like Peptide-1 A ...... rimental and Clinical Studies.

@en

Does Glucagon-like Peptide-1 A ...... rimental and Clinical Studies.

@nl

prefLabel

Does Glucagon-like Peptide-1 A ...... rimental and Clinical Studies.

@en

Does Glucagon-like Peptide-1 A ...... rimental and Clinical Studies.

@nl

P1433

Q37402790-2A5D1ABF-41B8-4B7E-AB3A-F0BFB5BB0E0C

P1476

Q37402790-8B77FD9F-05B0-489C-972C-8457E087DE2B

P2093

Q37402790-09B1D6E6-BFF6-4CE1-B78A-4C9131651FAD

Q37402790-ACCC2E31-ADEA-44EC-AB1C-5C02F66FF3A5

Q37402790-F8D4C0A6-BEE7-4A0E-8B54-3F083185DE19

P275

Q37402790-3F4D4D8A-9028-436A-8614-560761E05FB3

P2860

Q37402790-026D9490-EE01-4980-B917-CF067A71203D

Q37402790-09F059FD-8911-4F4F-A285-31FE5D7800C9

Q37402790-0A5F3C90-A2D1-433B-B1E7-EBD226AB78CC

Q37402790-0B0CDC0F-F448-4EAA-82E1-564565B66839

Q37402790-0BCBD06D-4AEB-4023-88D8-5765E9D34C53

Q37402790-0F96886F-AC37-4D04-8B0A-2033AA9D1DDD

Q37402790-0FACBE8E-6CBB-4020-9D22-5AEE1070F473

Q37402790-11B686A4-DD32-49FC-A986-B84AA3B5231C

Q37402790-1201D570-0B1D-4516-A907-E3E4FB68BD17

Q37402790-13683880-A63E-4C72-8ECE-8AA3A73095F6

P304

Q37402790-FE7730C5-2057-4883-8AB3-589E3045E6B0

P31

Q37402790-FE88124C-55A3-439A-B00C-EAEF563A77D9

P356

Q37402790-54DED436-C71C-439B-9F49-313282AC0E7C

P433

Q37402790-2D882925-F9C6-43DC-BD44-53914994B8B3

P478

Q37402790-00B746CA-41CF-4CE8-9FCA-FD2A717932D6

P50

Q37402790-8D1E6D94-ACC1-4AF4-A80E-16436BA6E089

P5008

Q37402790-D431D390-27F5-4E6D-9853-B597215DB904

P577

Q37402790-008C7C29-808F-431E-B198-077FF710557A

P698

Q37402790-C57B558D-0A70-4BA0-A9AB-B1C077B50946

P921

Q37402790-20A44142-A811-4C46-A89B-9B78B447A69F

Q37402790-4E132F2A-8A87-4CEE-BA5D-2BD74FE8B7E6

Q37402790-DD6A0492-2EEA-4EAA-9426-75C9FA1EA24B

P932

Q37402790-B8000DF0-CEA8-450D-9271-49507A02998D

P356

1573399812666150918150608

P1433

Current Diabetes Reviews

P1476

Does Glucagon-like Peptide-1 A ...... erimental and Clinical Studies

@en

P2093

Günaj Rakipovski

http://www.w3.org/2001/XMLSchema#string

Karen Ekkelund Petersen

http://www.w3.org/2001/XMLSchema#string

Kirsten Raun

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Atherosclerosis

Pharmacology, physiology, and mechanisms of incretin hormone action

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

Biochemistry and molecular cell biology of diabetic complications

P304

331-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1573399812666150918150608

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26381142

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

maturity-onset diabetes of the young

P932

5101636

http://www.w3.org/2001/XMLSchema#string